Cognision and SOMNOmedics: A Pioneering Partnership
Cognision, an industry leader in neurophysiological biomarker solutions, has teamed up with SOMNOmedics AG, known for their cutting-edge sleep diagnostics technology. This strategic alliance aims to revolutionize the integration of sleep biomarkers into pharmaceutical clinical trials, addressing the growing importance of sleep data in drug development.
Innovative Solutions for Clinical Trials
By merging their expertise, Cognision and SOMNOmedics are set to deliver next-gen polysomnography (PSG) solutions that meet the high demands of pharmaceutical-sponsored clinical trials. Cognision's proficiency in neurophysiological assessments complements SOMNOmedics' advanced PSG technology, creating a comprehensive framework for reliable sleep architecture data in therapeutic trials.
Importance of Sleep Endpoints
According to Dr. Igor Korolev, VP of Neuroscience and Digital Health for Cognision, the significance of sleep endpoints in central nervous system (CNS) drug development cannot be overstated. From conditions related to neurodegeneration to neuropsychiatric disorders and even pain management, understanding sleep patterns is crucial for effective drug efficacy testing. The collaboration promises to deliver top-tier PSG systems and streamlined processes that reduce complexity and enhance trial precision.
Enhanced Data Management and Integrity
The PSG systems from SOMNOmedics are known for their superior signal quality and flexibility for both inpatient and home use. This versatility supports decentralized clinical trials, allowing sponsors to choose the most appropriate setup for their needs. Moreover, all collected PSG data will be managed through Cognision's compliant cloud-based Clinical Trial Data Management System, enabling near real-time access for better decision-making and agile trial designs.
Setting New Benchmarks in Sleep Research
Denise Frahley, the Director of US Sales, emphasized that the partnership transcends mere equipment provision; it focuses on meeting and exceeding industry standards at every operational level. The innovative methodologies developed through this collaboration promise to redefine the standards for sleep measurement in pharmaceutical research, reinforcing Cognision's status as a preferred partner for neurophysiological endpoints in drug development.
About Cognision
Cognision specializes in advanced neurophysiological measurement services tailored for clinical trials, emphasizing the importance of EEG, ERP, and cognitive testing. Their comprehensive managed services encompass protocol consultation, logistics, site enablement, training, data oversight, and analytics, ensuring consistency and compliance across a variety of pharmaceutical studies.
About SOMNOmedics AG
SOMNOmedics is renowned for its innovation in portable and stationary sleep diagnostics. Their expertise in signal quality and adaptability empowers clinicians and researchers to gather high-quality sleep data for clinical research and patient care.
Frequently Asked Questions
What is the main goal of the Cognision and SOMNOmedics partnership?
The primary goal is to enhance the integration of sleep biomarkers into pharmaceutical trials, improving the overall quality and reliability of sleep data.
How do SOMNOmedics' PSG systems benefit clinical trials?
The PSG systems provide unmatched signal quality and the flexibility to be used in various settings, including both inpatient and home environments.
What expertise does Cognision bring to the partnership?
Cognision offers extensive experience in neurophysiological assessments, vital for obtaining accurate sleep data in regulated research environments.
Why is sleep data important in drug development?
Sleep data is crucial in understanding the efficacy and safety of drugs, particularly those targeting CNS-related conditions.
How will this partnership improve the drug development process?
The collaboration aims to streamline processes, enhance data management, and reduce timelines in clinical trials related to sleep disorders.
